RxSight (NASDAQ:RXST) Price Target Lowered to $35.00 at Stifel Nicolaus

RxSight (NASDAQ:RXST) had its target price lowered by Stifel Nicolaus from $40.00 to $35.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

A number of other analysts also recently weighed in on RXST. Wells Fargo & Company reissued an “equal weight” rating and issued a $42.00 price target (down from $56.00) on shares of RxSight in a report on Wednesday, December 11th. Jefferies Financial Group started coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research note on Monday. Finally, UBS Group started coverage on shares of RxSight in a research note on Friday, December 6th. They issued a “buy” rating and a $52.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $58.13.

RxSight Price Performance

Shares of RxSight stock opened at $30.72 on Monday. RxSight has a fifty-two week low of $26.29 and a fifty-two week high of $66.54. The firm has a fifty day moving average price of $40.61 and a two-hundred day moving average price of $47.38. The company has a market cap of $1.24 billion, a PE ratio of -37.01 and a beta of 1.20.

Insider Buying and Selling

In other RxSight news, Director Shweta Maniar sold 3,782 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now owns 10,902 shares of the company’s stock, valued at $500,183.76. This represents a 25.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00. Following the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,103,005.88. This represents a 6.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,002 shares of company stock worth $1,959,796 in the last quarter. 9.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On RxSight

A number of hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its holdings in RxSight by 6.0% during the 3rd quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after acquiring an additional 222,000 shares during the last quarter. State Street Corp boosted its stake in shares of RxSight by 8.3% in the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock valued at $40,417,000 after purchasing an additional 62,349 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of RxSight by 17.7% in the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock valued at $40,398,000 after purchasing an additional 122,775 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in shares of RxSight by 74.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the last quarter. Finally, Brown Capital Management LLC bought a new position in shares of RxSight in the 3rd quarter valued at about $26,813,000. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.